SCHEMBL7792969

SCHEMBL7792969

Cc1cc(C)c(-n2c3ccccc3c3c(NC(=O)CN(C)C)cc(C)nc32)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.45
NPY5R Q15761 4/20 0.40
HTT P42858 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GALR3 O60755 1/20 0.38
POLB P06746 2/20 0.38
NR4A1 P22736 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPT P10636 3/20 0.38
PARP14 Q460N5 1/20 0.37
PIK3CD O00329 1/20 0.36
PIK3R1 P27986 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7676276 0.77 CRHR1 (0.49) CRHR1RXFP1
SCHEMBL7783147 0.76 CRHR1 (0.53) CRHR1KDM4ETSHR
SCHEMBL7677887 0.75 CRHR1 (0.45) CRHR1RAB9ASMN1; SMN2MAPTKDM4E
SCHEMBL7675031 0.75 CRHR1 (0.45) CRHR1
SCHEMBL7788156 0.75 CRHR1 (0.47) CRHR1SMN1; SMN2LMNA
SCHEMBL7684798 0.74 CRHR1 (0.51) CRHR1MAPTKDM4ELMNATSHR
SCHEMBL7215931 0.73 CRHR1 (0.57) CRHR1TDP1
SCHEMBL7677531 0.73 CRHR1 (0.53) CRHR1SMN1; SMN2POLBTDP1KDM4E
SCHEMBL7791105 0.72 CRHR1 (0.41) CRHR1
SCHEMBL7783167 0.71 TP53 (0.39) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NEUROGEN CORPORATION 2001-10-18 US claimed
US-6221875-B1 TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL NEUROGEN CORPORATION 2001-04-24 US claimed
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NEUROGEN CORPORATION 2001-10-18 US disclosed
US-6221875-B1 TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL NEUROGEN CORPORATION 2001-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NPY1R, NPY2R, NPY5R CRHR1 33/4885NPY5R 3/4885HTT 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.